These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 22258961)
41. Treatment of long-distance intermittent claudication with pentoxifylline: a 12-month, randomized trial. De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Incandela L; Bucci M; Geroulakos G; Ramaswami G; Vasdekis S; Agus G; Bavera P; Ippolito E Angiology; 2002; 53 Suppl 1():S13-7. PubMed ID: 11865829 [TBL] [Abstract][Full Text] [Related]
42. A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly. Ciocon JO; Galindo-Ciocon D; Galindo DJ Angiology; 1997 Mar; 48(3):237-40. PubMed ID: 9071199 [TBL] [Abstract][Full Text] [Related]
43. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication. Shahin Y; Barnes R; Barakat H; Chetter IC Atherosclerosis; 2013 Dec; 231(2):283-90. PubMed ID: 24267241 [TBL] [Abstract][Full Text] [Related]
44. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281 [TBL] [Abstract][Full Text] [Related]
45. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990 [TBL] [Abstract][Full Text] [Related]
46. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Momsen AH; Jensen MB; Norager CB; Madsen MR; Vestersgaard-Andersen T; Lindholt JS Eur J Vasc Endovasc Surg; 2009 Oct; 38(4):463-74. PubMed ID: 19586783 [TBL] [Abstract][Full Text] [Related]
47. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis. Liang X; Wang Y; Zhao C; Cao Y PLoS One; 2022; 17(11):e0275392. PubMed ID: 36318524 [TBL] [Abstract][Full Text] [Related]
48. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks. Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717 [TBL] [Abstract][Full Text] [Related]
49. Treatment of intermittent claudication with pentoxifylline and cilostazol. Tjon JA; Riemann LE Am J Health Syst Pharm; 2001 Mar; 58(6):485-93; quiz 494-6. PubMed ID: 11286146 [TBL] [Abstract][Full Text] [Related]
50. The effect of withdrawal of drugs treating intermittent claudication. Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267 [TBL] [Abstract][Full Text] [Related]
53. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication. Mangiafico RA; Messina R; Attinà T; Dell'Arte S; Giuliano L; Malatino LS Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853 [TBL] [Abstract][Full Text] [Related]
54. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Shahin Y; Mazari F; Chetter I Int J Surg; 2011; 9(3):209-13. PubMed ID: 21195215 [TBL] [Abstract][Full Text] [Related]
55. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Guest JF; Davie AM; Clegg JP Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881 [TBL] [Abstract][Full Text] [Related]
56. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952 [TBL] [Abstract][Full Text] [Related]
57. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication. Delaney CL; Spark JI; Thomas J; Wong YT; Chan LT; Miller MD Atherosclerosis; 2013 Jul; 229(1):1-9. PubMed ID: 23557982 [TBL] [Abstract][Full Text] [Related]
58. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. Gillings DB J Cardiovasc Pharmacol; 1995; 25 Suppl 2():S44-50. PubMed ID: 8699861 [TBL] [Abstract][Full Text] [Related]
59. Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months of treatment. Panchenko E; Eshkeeva A; Dobrovolsky A; Titaeva E; Podinovskaya Ya; Hussain KM; Karpov Yu Angiology; 1997 Mar; 48(3):247-54. PubMed ID: 9071201 [TBL] [Abstract][Full Text] [Related]